Searching journal content for bisphosphonates (as phrase) in full text.

Displaying results 1-10 of 43

For checked items

view abstracts
download to citation manager

Select this article
Thematic Review:
- Robert C Mould,
- Jacob P van Vloten,
- Amanda W K AuYeung,
- Khalil Karimi,
- and Byram W Bridle
Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission Endocr Relat Cancer 24 (12) T311-T329, doi:10.1530/ERC-17-0316 first published on 14 September 2017
...bisphosphonates ~~~
Select this article
Review:
- Catherine Zabkiewicz,
- Jeyna Resaul,
- Rachel Hargest,
- Wen Guo Jiang,
- and Lin Ye
Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance Endocr Relat Cancer 24 (10) R349-R366, doi:10.1530/ERC-17-0139 first published on 21 July 2017
...bisphosphonates and denosumab is currently a palliative measure, because they have not been consistently shown to improve survival or prevent bone metastasis. Moreover, breast cancer patients who develop pathological fracture have a significant 32% increased risk of death relative to patients withou ~~~
OPEN ACCESS ARTICLE
Select this article
Review:
- Anna Angelousi,
- Georgios K Dimitriadis,
- Georgios Zografos,
- Svenja Nölting,
- Gregory Kaltsas,
- and Ashley Grossman
Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies Endocr Relat Cancer 24 (6) R239-R259, doi:10.1530/ERC-16-0542 first published on 11 April 2017
...bisphosphonates ~~~
Select this article
Review:
- Caroline Wilson,
- Hannah Brown,
- and Ingunn Holen
The endocrine influence on the bone microenvironment in early breast cancer Endocr Relat Cancer 23 (12) R567-R576, doi:10.1530/ERC-16-0238 first published on 29 September 2016
...bisphosphonates f reproductive hormones R568Review C Wilson et al. Hormones influence breast cancer in bone DOI: 10.1530/ERC-16-0238 http://.endocrinology-journals.org © 2016 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd. 23:12 clinical setting. The environment p ~~~
Select this article
Review:
- Georgios K Dimitriadis,
- Martin O Weickert,
- Harpal S Randeva,
- Gregory Kaltsas,
- and Ashley Grossman
Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours Endocr Relat Cancer 23 (9) R423-R436, doi:10.1530/ERC-16-0200 first published on 26 July 2016
...bisphosphonates ~~~
Select this article
Research:
- María Rodríguez-Sanz,
- Daniel Prieto-Alhambra,
- Sonia Servitja,
- Natalia Garcia-Giralt,
- Laia Garrigos,
- Jaime Rodriguez-Morera,
- Joan Albanell,
- Maria Martínez-García,
- Iria González,
- Adolfo Diez-Perez,
- Ignasi Tusquets,
- and Xavier Nogués
AI-related BMD variation in actual practice conditions: A prospective cohort study Endocr Relat Cancer 23 (4) 303-312, doi:10.1530/ERC-16-0025 first published on 24 February 2016
...bisphosphonates (BPs). Of 685 women recruited, 179 (26.1%) received BP treatment. By the third year of AI therapy, this group exhibited increased BMD in the lumbar spine (LS; 2.59%) and femoral neck (FN; 2.50%), although the increase was significant only within the first year (LS: 1.99% and FN: 2.04 ~~~
Select this article
Research:
- Penelope D Ottewell,
- Ning Wang,
- Joshua Meek,
- C Anne Fowles,
- Peter I Croucher,
- Colby L Eaton,
- and Ingunn Holen
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone Endocr Relat Cancer 21 (5) 769-781, doi:10.1530/ERC-14-0199 first published on 22 July 2014
...bisphosphonates – what have we learned from in vivo models? Current Cancer Drug Targets 9 807–823. (doi:10.2174/156800909789760339) Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson MC, You S, Kim J et al. 2014 RANK- and c-Met-mediated signal network promotes prostate can ~~~
Select this article
Review:
- Ada S Cheung,
- Jeffrey D Zajac,
- and Mathis Grossmann
Muscle and bone effects of androgen deprivation therapy: current and emerging therapies Endocr Relat Cancer 21 (5) R371-R394, doi:10.1530/ERC-14-0172 first published on 23 July 2014
...bisphosphonates to prevent loss of bone mass have included supplementation for all participants (Table 4). Despite some controversy, for men undergoing ADT who are at high risk of bone decay, general lifestyle measures of regular aerobic, weight-bearing and resistance exise, minimization of alcohol ~~~
Select this article
Commentary:
- Paramita M Ghosh and
- Allen C Gao
Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice Endocr Relat Cancer 21 (5) C11-C14, doi:10.1530/ERC-14-0387 first published on 2 September 2014
...bisphosphonates ~~~
Select this article
Thematic Review:
- Carolyn A Allan,
- Veronica R Collins,
- Mark Frydenberg,
- Robert I McLachlan,
- and Kati L Matthiesson
Androgen deprivation therapy complications Endocr Relat Cancer 21 (4) T119-T129, doi:10.1530/ERC-13-0467 first published on 28 May 2014
...bisphosphonates are less well studied, but aledronate prevented bone loss over 12 months (Greenspan et al. 2007, 2008) and beyond. A meta-analysis of 15 bisphosphonate studies including 2634 men receiving ADT documented a reduction in fracture risk (RR, 0.80; PZ0.005) and osteoporosis (RR, 0.39; P!0 ~~~

For checked items

view abstracts
download to citation manager

Endocrine-Related Cancer

Searching journal content for bisphosphonates (as phrase) in full text.

Search Results

Modify Results

This search

New Articles: issue in progress

Most

Viewed

Cited

Citation format:
Results / page:
Results order: